Design, Synthesis, and Structure-Activity Relationships of Biaryl Anilines as Subtype-Selective PPAR-alpha Agonists

Area of Science:

• Medicinal Chemistry
• Ophthalmology
• Molecular Pharmacology

Background:

• Peroxisome proliferator-activated receptor alpha (PPARα) plays a crucial role in retinal biology.
• Emerging evidence highlights PPARα agonists as potential therapeutics for diabetic retinopathy and age-related macular degeneration.

Purpose of the Study:

• To design and characterize a novel biaryl aniline chemotype targeting PPARα.
• To investigate structure-activity relationships and subtype selectivity for PPARα agonism.

Main Methods:

• Design and synthesis of a new series of biaryl aniline compounds.
• Evaluation of PPARα agonistic activity using cell-based luciferase assays.
• Assessment of subtype selectivity against other PPAR isoforms.

Main Results:

• The novel biaryl aniline series demonstrated potent PPARα agonism with <90 nM potency.
• Compounds exhibited subtype selectivity for PPARα over other isoforms, attributed to the benzoic acid headgroup.
• Lead compounds (3g, 6j, 6d) showed efficacy in disease-relevant cellular contexts.

Conclusions:

• The identified biaryl aniline chemotype represents a promising starting point for developing novel PPARα-targeted therapies for retinal diseases.
• Further in vitro and in vivo studies are warranted to fully characterize the therapeutic potential of these lead compounds.